← Back to patent-cliff list
Epivotide
Tier C — Watch / tradeEpivotide
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：PI3Kγ
Indications (approved)：Keratitis, Dry eye disease, Perennial allergic rhinitis, Allergic rhinitis, 烧伤, 角膜疾病, Common cold, Inflammatory disease
Regional status
US
-
EU
-
China
Phase II
2021-08-04
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Epivotide?
Approved indications include: Keratitis, Dry eye disease, Perennial allergic rhinitis, Allergic rhinitis, 烧伤, 角膜疾病, Common cold, Inflammatory disease.
When does the Epivotide patent expire?
No public expiry year is available for Epivotide yet; this page updates once verified.
How do I get a quote for Epivotide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21